Stay current on changes and developments in corporate law with a wide variety of resources and tools.
March 30 — Shire Plc investors can't proceed with a putative class action accusing AbbVie Inc. of violating federal securities laws by making false and misleading statements in connection with the companies' failed tax inversion deal, a federal judge ruled March 29.
Judge Robert M. Dow Jr. from the U.S. District Court for the Northern District of Illinois said the investors hadn't adequately pleaded that AbbVie made material misrepresentations in statements made before the merger was abandoned.
The court also concluded that AbbVie Chief Executive Officer Richard Gonzalez didn't act with scienter—or improper intent—in expressing enthusiasm about the deal in a statement sent to Shire employees and filed with the Securities and Exchange Commission a week after the U.S. Treasury Department said it would take steps to stymie tax inversions.
The court dismissed the investors' lawsuit without prejudice, giving them until May 2 to file an amended complaint.
North Chicago, Ill.-based AbbVie planned to buy Shire for an estimated $52 billion, then move the combined company's legal address to the U.K. to lower its tax bill and access cash trapped overseas. As part of the deal, AbbVie agreed to pay a termination fee of $1.64 billion if the transaction wasn't completed.
The two companies in October 2014 agreed to terminate what would have been the biggest U.S. tax inversion at the time after AbbVie pulled its support for the deal in the wake of proposed changes to U.S. rules governing such transactions .
In their lawsuit, the investors alleged that AbbVie violated 1934 Securities Exchange Act Sections 10(b) and 20(a) by downplaying or denying that the tax inversion was “the make-or-break reason for the merger.”
The court concluded that AbbVie's statements disclosing the deal's benefits didn't create a corresponding duty to disclose that it might call off the acquisition and pay the breakup fee if the tax benefits disappeared.
Additionally, Gonzalez's statement that tax benefits weren't the “primary rationale” for the merger wasn't materially misleading, the court found.
The court observed that the breakup fee was about 3 percent of the deal's value and that it was expected that the loss of any benefit over this threshold could cause AbbVie to terminate the transaction.
“But it does not follow that any benefit of the deal that is worth at least 3% of the transaction value must be the ‘primary'—i.e. the ‘most important'—reason for the deal,” Dow wrote. He added that the defendants correctly pointed out that saying a benefit isn't the “primary rationale” isn't the same as saying it's “immaterial or unimportant.”
To contact the reporter on this story: Michael Greene in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Yin Wilczek at email@example.com
The opinion is available at http://www.bloomberglaw.com/public/document/Rubinstein_v_Gonzalez_No_14cv9465_2016_BL_96777_ND_Ill_Mar_29_201.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)